10x Genomics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of 10x Genomics generated cash of -$15,197,000, which is more than the previous year. Cash used in financing activities reached the amount of $13,669,000 last year. Net change in cash is therefore $131,931,000.
Cash Flow
| 2017 | -10.69M | -3.75M | 20.58M |
|---|---|---|---|
| 2018 | -76.40M | -6.70M | 105.36M |
| 2019 | 34.62M | -42.76M | 414.59M |
| 2020 | -217.89M | -38.39M | 468.90M |
| 2021 | -21.37M | -106.72M | 35.29M |
| 2022 | -33.60M | -350.88M | 15.81M |
| 2023 | -15.19M | 133.49M | 13.66M |
TXG Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 227.35M | 596.07M | 688.64M | 476.49M | 70.08M | 47.85M | 41.74M |
Operating activities | |||||||
Net income | -255.09M | -166M | -58.22M | -542.73M | -31.25M | -112.48M | -18.76M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 43.61M | 33.00M | 28.25M | 19.02M | 7.06M | 3.90M | 4.30M |
Stock-based compensation expense | 166.95M | 136.84M | 95.96M | 48.62M | 13.33M | 0 | 1.66M |
| Deferred income tax benefit | 166.95M | 136.84M | 95.96M | 48.62M | 13.33M | 0 | 1.66M |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -10.61M | -18.94M | -34.04M | -17.84M | -5.28M | -14.74M | -5.13M |
Inventories | 7.87M | -21.19M | -30.13M | -14.60M | -6.69M | -3.73M | -1.99M |
Accounts payable | -6.01M | 5.85M | 11.08M | -7.77M | 4.90M | 2.58M | 3.03M |
Cash generated by operating activities | -15.19M | -33.60M | -21.37M | -217.89M | 34.62M | -76.40M | -10.69M |
Investing activities | |||||||
Purchases Of Investments | 0 | -282.87M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -48.60M | -131.66M | -101.27M | -38.39M | -42.76M | -6.70M | -3.75M |
Acquisitions Net | 0 | -4M | -5.45M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 133.49M | -350.88M | -106.72M | -38.39M | -42.76M | -6.70M | -3.75M |
Financing activities | |||||||
Common Stock Issued | 19.48M | 21.22M | 40.32M | 506.01M | 410.82M | 1.79M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -80K |
Repayments of term debt | 0 | 0 | -5.02M | -37.10M | 0 | -773K | -393K |
Cash used in financing activities | 13.66M | 15.81M | 35.29M | 468.90M | 414.59M | 105.36M | 20.58M |
Net Change In Cash | 131.93M | -368.72M | -92.57M | 212.15M | 406.40M | 22.23M | 6.11M |
Cash at end of period | 359.28M | 227.35M | 596.07M | 688.64M | 476.49M | 70.08M | 47.85M |
| Data source | Data source | Data source | Data source | Data source |